Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (TSE:FRX)
TSX:FRX
RESEARCH TOOLSreports
Fennec Pharmaceuticals (FRX) Stock Price & Analysis
3 Followers
FRX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$9.09 - C$17.00
Previous CloseC$12.58
Volume2.00
Average Volume (3M)614.00
Market Cap
C$340.92M
Enterprise ValueC$363.47M
Total Cash (Recent Filing)$13.27M
Total Debt (Recent Filing)$29.73M
Price to Earnings (P/E)-15.4
Beta0.04
Next Earnings
May 09, 2024EPS Estimate
-C$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding26,633,000
10 Day Avg. Volume200
30 Day Avg. Volume614
Standard Deviation0.15
R-Squared0.01
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-21.29
Price to Sales (P/S)35.03
Price to Cash Flow (P/CF)-12.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.10
Enterprise Value/Gross Profit18.18
Enterprise Value/Ebitda-29.40
Forecast
1Y Price Target
C$25.53Price Target Upside102.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Fennec Pharmaceuticals News
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Strong 2023 Growth
PremiumCompany Announcements
Fennec Pharmaceuticals Files SEC 8-K Report
PremiumCompany Announcements
Fennec Pharmaceuticals’ Soaring Sales and New DealFRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$9.09 and its highest was C$17.00 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Currently, no data Available
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 7 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Mar 21, 2024. The company reported -C$0.137 earnings per share for the quarter, missing the consensus estimate of -C$0.025 by -C$0.112.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -C$0.08.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 27,099,909 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -C$0.137 in its last earnings report, missing expectations of -C$0.025. Following the earnings report the stock price went down -3.654%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
---
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$25.53 (102.93% Upside)
C$25.53 (102.93% Upside)
Blogger Sentiment
Neutral
TSE:FRX Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $31.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.28%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
---
FRX Earnings Call
Q4 2024
0:00 / 0:00
---
FRX Stock 12 Months Forecast
Average Price Target
C$25.53
▲(102.93% Upside)
Technical Analysis
Fennec Pharmaceuticals
―
Apellis Pharmaceuticals
―
Cidara Therapeutics
―
Curis
―
Durect
―
Best Analysts Covering FRX
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+12.39%
assigned a buy rating last month
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +12.39% per trade.
---